Live from the NIH registry
Studies recruiting near Myrtle Beach right now
Top 25 of 89 recruiting studies, sorted by proximity — each links to its official registry page
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
Transitional Cell Cancer of Renal Pelvis and Ureter
Phase 3
Interventional 100 participants sought
Carolina Urologic Research Center — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: Steba Biotech S.A.
A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
Nonmuscle-invasive Bladder Cancer
Phase 2
Interventional 160 participants sought
Carolina Urologic Research Center — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: ImmVira Pharma Co. Ltd
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Metastatic Hormone-sensitive Prostate Cancer
Phase 2
Interventional 150 participants sought
Carolina Urologic Research Center — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: Novartis Pharmaceuticals
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Phase 2
Interventional 90 participants sought
Site 02-006 - Carolina Urologic Research Center — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: Theralase® Technologies Inc.
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Phase 3
Interventional 750 participants sought
South Texas Accelerated Research Therapeutics - Carolinas — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: Amgen
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Non-muscle-invasive Bladder Cancer, NMIBC
Phase 1
Interventional 55 participants sought
Carolina Urologic Research Center — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: Aura Biosciences
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
Prostate Cancer
Phase 1, Phase 2
Interventional 300 participants sought
Research Site — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: AstraZeneca
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Non-Muscle Invasive Bladder Neoplasms
Phase 3
Interventional 641 participants sought
Carolina Urologic Research Center — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: Janssen Research & Development, LLC
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Alopecia Areata
Phase 3
Interventional 1,330 participants sought
Alliance for Multispecialty Research, LLC — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: Pfizer
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Prostatic Neoplasms, Castration-Resistant
Phase 3
Interventional 800 participants sought
Carolina Urologic Research Center — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: Janssen Research & Development, LLC
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer
Phase 2
Interventional 100 participants sought
Carolina Urologic Research Center — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: Hoffmann-La Roche
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Urinary Bladder Neoplasms, Neoplasm Metastasis
Phase 1
Interventional 677 participants sought
Carolina Urologic Research Center — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: Eli Lilly and Company
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Phase 1
Interventional 60 participants sought
South Texas Accelerated Research Therapeutics - Carolinas — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: Amgen
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostatic Neoplasms
Phase 3
Interventional 1,203 participants sought
Carolina Urologic Research Center — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: Janssen Research & Development, LLC
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
Pain
N/A
Observational 4,800 participants sought
Channel Research — Pawleys Island, South Carolina (23.5 mi)
· Sponsor: Boston Scientific Corporation
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Phase 1, Phase 2
Interventional 350 participants sought
Carolina Urologic Research Center, LLC — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: enGene, Inc.
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
Phase 1
Interventional 88 participants sought
Carolina Urologic Research Center — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: Acerand Therapeutics (Hong Kong) Limited
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Bladder Carcinoma, Ureter Carcinoma
N/A
Observational 2,020 participants sought
Carolina Urologic Research Center — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: Guardant Health, Inc.
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Oligometastatic Prostate Cancer (OMPC)
Phase 3
Interventional 450 participants sought
Carolina Urologic Research Center — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: Novartis Pharmaceuticals
Prospective Post Market Clinical Registry for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH Spring System Registry
BPH (Benign Prostatic Hyperplasia)
N/A
Observational 300 participants sought
START Research — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: Zenflow, Inc.
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
Insomnia Disorder
Phase 3
Interventional 420 participants sought
Vanda Investigational Site — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: Vanda Pharmaceuticals
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Metastatic Castration-Resistant Prostate Cancer
Phase 3
Interventional 900 participants sought
AUC Urologists, LLC — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: Pfizer
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Non-muscle Invasive Bladder Cancer
Phase 1
Interventional 294 participants sought
Grand Strand Medical Center — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: Pfizer
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Non-muscle-invasive Bladder Cancer
Phase 1, Phase 2
Interventional 75 participants sought
Carolina Urologic Research Center — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: SURGE Therapeutics
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Solid Tumor Cancer, Locally Advanced
Phase 1, Phase 2
Interventional 355 participants sought
Avenzo Therapeutics Recruiting Site — Myrtle Beach, South Carolina (1.4 mi)
· Sponsor: Avenzo Therapeutics, Inc.